After chemo, surviving ovarian cancer cells may use a common sugar to push neighbors to spread

After cisplatin, the ovarian cancer cells that survive treatment don't go quiet. A Nature Aging study from the Wistar Institute shows they release fructose, the simple sugar found in fruit and table sugar, and in mice that chemical message loosened neighboring tumors' grip on their surroundings and let them spread. The result, published July 30, is among the first demonstrations that a dietary nutrient can act as a paracrine signal — a message passed between neighboring cells — rather than just a metabolic fuel.

The stakes sit in metastasis. Ovarian cancer is one of the deadliest gynecologic cancers, and metastasis, the seeding of new tumors beyond the ovary, drives about 90% of those deaths. Nearly every patient gets platinum-based chemotherapy, and the tumors usually respond at first. The problem is that the disease comes back in most cases, often in places chemotherapy reaches poorly.

A team led by Aidan Cole in Katherine Aird's lab at the Wistar Institute asked what the chemo-surviving cells were doing during that window. The cells had stopped dividing — a state biologists call senescence — but they were not inert. As part of the senescence-associated secretory phenotype (SASP), they poured out a mixture of signaling molecules. Fructose was one of them, and it was the one that mattered.

The researchers showed that fructose released by these senescent cells acted on neighboring cancer cells, not as food but as a chemical message. It hit an axis involving NAD+, the SIRT proteins, and the cholesterol regulator SREBP, lowering the amount of cholesterol in the neighboring cells' plasma membranes. With less membrane cholesterol to anchor them, the cells detached more easily from the ovarian tissue and entered the bloodstream — an early step toward metastasis.

In mouse models of high-grade serous ovarian cancer (HGSOC), the most aggressive form, the released substances significantly increased the cancer's ability to spread. A high-fructose diet made the dissemination worse. The team traced the chain back to mitochondrial complex I — the first enzyme of the cell's energy-producing electron transport chain — and identified it as the engine driving SASP-mediated cell detachment.

That is the framing that breaks the standard "sugar feeds cancer" story. In this work, fructose is not feeding the tumor. It is being used by chemo-surviving tumor cells to recruit their neighbors into leaving.

The caveats are loud. Every experiment was preclinical — in cultured cells and in mice, not in patients. The dietary implication, that eating less fructose might slow ovarian cancer spread, is an open research question the authors flag but do not answer. The companion idea, that cholesterol-lowering drugs such as statins could influence progression, is similarly downstream and untested in this work.

What the result does support is a new way to look at the post-chemotherapy tumor microenvironment, and a specific, testable hypothesis: if senescent cancer cells use fructose as a signal, blocking that signal — or the mitochondrial complex I that produces it — could slow metastasis. The authors say clinical translation is the next step. Both ideas now need human studies.

Until those studies land, the strongest claim the data support is narrow: in mice, fructose released by chemo-surviving ovarian cancer cells made neighboring tumors more likely to break free. Whether the same signal runs in patients is the question worth watching.